Richard Quek - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Richard Quek

Showing results (71-80 of 74) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 74 results.

Cancer Reports (Hoboken, N.J.)|April 28, 2022

Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapyTricia Tay, Nagavalli Somasundaram, Cindy Lim, et al.

Cancer Discovery|June 19, 2012

Janus kinase 3-activating mutations identified in natural killer/T-cell lymphomaGhee Chong Koo, Soo Yong Tan, Tiffany Tang, et al.

Gut|September 5, 2015

SETD2 histone modifier loss in aggressive GI stromal tumoursKie Kyon Huang, John R McPherson, Su Ting Tay, et al.

The Lancet. Oncology|July 30, 2016

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association studyZheng Li, Yi Xia, Li-Na Feng, et al.

Pageof 8

Search research articles

Showing results (71-80 of 74) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 74 results.

Cancer Reports (Hoboken, N.J.)|April 28, 2022

Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapyTricia Tay, Nagavalli Somasundaram, Cindy Lim, et al.

Cancer Discovery|June 19, 2012

Janus kinase 3-activating mutations identified in natural killer/T-cell lymphomaGhee Chong Koo, Soo Yong Tan, Tiffany Tang, et al.

Gut|September 5, 2015

SETD2 histone modifier loss in aggressive GI stromal tumoursKie Kyon Huang, John R McPherson, Su Ting Tay, et al.

The Lancet. Oncology|July 30, 2016

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association studyZheng Li, Yi Xia, Li-Na Feng, et al.

Pageof 8